Parabilis Medicines
Amber Wells is a seasoned professional in clinical science with extensive experience across prominent pharmaceutical organizations. Currently serving as Senior Director of Clinical Science at FogPharma since May 2024, Amber previously held leadership roles such as Director of Clinical Science and Sr. Clinical Scientist at Bristol Myers Squibb from April 2020 to May 2024. Prior to that, Amber was a Clinical Research Scientist at Celgene and managed clinical research at Amgen. With a background that includes positions at Arvinas, Inc., Pfizer, OSI Pharmaceuticals, and academic experience as an Assistant Professor at Albert Einstein College of Medicine, Amber has a strong foundation in translational and clinical science, bolstered by a PhD in Cell and Molecular Biology from the University of Pennsylvania and a BS in Physiological Science from UCLA.
This person is not in any teams
Parabilis Medicines
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit: www.parabilismed.com